Astellas
ABPI reveals 10% increase in HCP payment disclosure
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, disclosure, disclosure uk
The headline news from the ABPI’s press conference on Disclosure UK was that healthcare professionals’ (HCPs) disclosure of payments for …
Astellas receives further year suspension from ABPI
June 26, 2017Medical Communications, Sales and Marketing ABPI, Astellas
The Association of the British Pharmaceutical Industry (ABPI) has announced that it has taken the unusual step of extending the …
Astellas lines up Ogeda for acquisition in $853 million deal
April 3, 2017Sales and Marketing Astellas, Ogeda SA, menopause
Astellas, based in Tokyo, has announced that it has agreed a deal to acquire Belgium-based Ogeda SA. The deal will …
Astellas and Ironwood release positive Phase 3 results for constipation drug
January 30, 2017Research and Development, Sales and Marketing Astellas, Ironwood, constipation
Astellas Pharma, a Tokyo-based pharmaceutical, and Ironwood Pharmaceuticals, based in Cambridge, Massachusetts, have announced positive results from a Phase 3 …
Astellas snatches up oncology firm Ganymed for $1.4 billion
October 31, 2016Research and Development, Sales and Marketing Astellas, Ganymed, IMAB362
Japanese pharma firm Astellas is set to bolster its oncology business with the acquisition of Ganymed Pharmaceuticals in a deal …
Astellas UK suspended from ABPI for “deception” and other cultural failings
June 24, 2016Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, cultural failings
Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for a period …
US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi
March 30, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price
US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …
Phase III trial initiated for enzalutamide in treatment of prostate cancer
March 24, 2016Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer
Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
Japan approves Astellas hyperphosphatemia drug
March 1, 2016Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Hyperphosphatemia, Japan, Kiklin
Astellas Pharma has received approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug …
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
Astellas investigated for ‘misleading’ PMCPA during ABPI code complaint
December 18, 2015Medical Communications ABPI Code, Astellas, Astellas Pharma Europe, PMCPA, Prescription Medicines Code of Practice Authority
The Prescription Medicines Code of Practice Authority is investigating Astellas for deliberately providing an ‘incomplete and misleading’ response to a …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
LEO Pharma buys dermatology portfolio from Astellas
November 12, 2015Sales and Marketing Astellas, LEO Pharma, acquisitions, dermatology, mergers
LEO Pharma, the speciality dermatology firm, is looking to expand its presence in the therapy area by buying Astellas’ portfolio …
Astellas to acquire Ocata Therapeutics in $379m buyout
November 11, 2015Research and Development, Sales and Marketing Astellas, Ocata, Stem cells, cell therapy, ophthalmology
Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …
Jamie McGarvey joins Astellas Pharma communications team
September 18, 2015Medical Communications Astellas, Astellas Pharma, Jamie McGarvey
Astellas Pharma has appointed Jamie McGarvey as senior manager of employee communications within its corporate affairs department. McGarvey will be …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
